You are using an outdated browser. We suggest you update your browser for a better experience. Click here for update.
Close this notification.
Skip to main content Skip to search

Certaines de ces informations ou toutes, dans certains cas, n’apparaissent qu’en Anglais. Vous pouvez demander la version française

 

190 Results
Regimen
Cancer Type:
Gastrointestinal, 
Pancreas
Intent: Adjuvant
Nov 2022
Regimen
Cancer Type:
Lung, 
Non-Small Cell
Intent: Palliative
Funding:
Exceptional Access Program
    gefitinib - First-line monotherapy in locally advanced (not amenable to curative therapy) or metastatic NSCLC patients who have activating mutations of EGFR-TK, with specific criteria
Mar 2021
Regimen
Cancer Type:
Hematologic, 
Lymphoma - Non-Hodgkin's High Grade, 
Lymphoma - Non-Hodgkin's Intermediate Grade
Intent: Curative, Palliative
Funding:
ODB - General Benefit
    dexamethasone
Regimen
Cancer Type:
Hematologic, 
Lymphoma - Hodgkin
Intent: Curative, Palliative
Funding:
ODB - General Benefit
    dexamethasone
Regimen
Cancer Type:
Hematologic, 
Leukemia - Chronic Myeloid (CML)
Intent: Palliative
Funding:
Exceptional Access Program
    niLOtinib - Chronic phase Ph+ CML, with specific criteria
Exceptional Access Program
    niLOtinib - Accelerated phase Ph+ CML with documented resistance or intolerance to imatinib therapy, with specific criteria
Mar 2023
Regimen
Cancer Type:
Genitourinary, 
Testis
Intent: Palliative
Jan 2018
Regimen
Cancer Type:
Gynecologic, 
Uterine Sarcoma, 
Sarcoma, 
Uterine
Intent: Palliative
Regimen
Cancer Type:
Genitourinary, 
Prostate
Intent: Palliative
Funding:
ODB - General Benefit
  • niLUTAmide
Sep 2018
Regimen
Cancer Type:
Gastrointestinal, 
Pancreas
Intent: Palliative
Funding:
New Drug Funding Program
    Gemcitabine and Nab-Paclitaxel - Advanced Pancreatic Cancer
Nov 2023
Regimen
Intent: Adjuvant, Palliative
Funding:
ODB - General Benefit
  • goserelin
Sep 2017
Regimen
Intent: Palliative
Funding:
New Drug Funding Program
    Nab-Paclitaxel - Metastatic Breast Cancer
Nov 2023

Pages